Monoclonal Antibodies mAbs Biosimilars Market Size,
Share 2026
Market Intelligence Overview
Monoclonal Antibodies (mAbs) Biosimilars Market Insights
Global Monoclonal Antibodies (mAbs) Biosimilars market was valued at 13652 million in 2025 and is projected to reach USD 46310 million by 2034, at a CAGR of 18.6% during the forecast period.
Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.
Current Market Size
13,652
USD Million
Global market valuation recorded in 2025
● Established Industry Position
↗
Projected
Market Expansion
Forecast Outlook
46,310
USD Million
Expected global market value by 2034
▲ Strong Long-Term Potential
Leading Region
North America
Emerging Region
Asia-Pacific
Industry Perspective
Strategic Market Outlook
Analyst View
Demand growth is being driven by the expansion of biosimilar competition into high‑spend reference biologics such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab, with a second wave now targeting ustekinumab, tocilizumab and other emerging targets.
Future differentiation will rely on high‑concentration formulations, citrate‑free presentations, prefilled syringes, autoinjectors and interchangeability designations, while the U.S. and Europe remain the most valuable regulated markets.
Competitive Environment
Key Participants
🏢
Celltrion, Inc.
Samsung Bioepis Co., Ltd.
Amgen Inc.
Sandoz Group AG
Pfizer Inc.
Long‑term pharmaceutical demand and rising treatment awareness are expected to sustain healthy market expansion across both developed and emerging healthcare ecosystems.
MARKET DYNAMICS
MARKET DRIVERS
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast perio
,
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time-consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long-term safety and potential unintended effects of gene editing technologies such as CRISPR-Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
,
MARKET RESTRAINTS
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off-target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA-modifying enzymes.
,
MARKET OPPORTUNITIES
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future GrowthRising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
Segment Analysis:
By Type
TNF‑α Inhibitors Segment Dominates the Market Due to High Demand in Autoimmune Therapies
The market is segmented based on type into:
-
Adalimumab Biosimilars
-
Infliximab Biosimilars
-
Rituximab Biosimilars
-
Trastuzumab Biosimilars
-
Bevacizumab Biosimilars
-
Ranibizumab Biosimilars
-
Ustekinumab Biosimilars
-
Tocilizumab Biosimilars
-
Denosumab Biosimilars
-
Other mAb Biosimilars
By Application
Oncology Segment Leads Due to Expanding Biosimilar Competition in High‑Value Cancer Treatments
The market is segmented based on application into:
-
Oncology
-
Autoimmune and Inflammatory Diseases
-
Ophthalmology
-
Bone Disease and Osteoporosis
-
Hematology and Rare Diseases
-
Asthma and Allergy
-
Others
COMPETITIVE LANDSCAPE
Key Industry Players
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the global Monoclonal Antibodies (mAbs) Biosimilars market is semi‑consolidated, with large, medium and niche players. The market was valued at US$13,652 million in 2025 and is projected to reach US$46,310 million by 2034, expanding at a CAGR of 18.6 %. This rapid growth is driven by expanding biosimilar pipelines, cost‑pressures on healthcare systems and the widening acceptance of interchangeable products.
Celltrion Inc. and Samsung Bioepis Co., Ltd. are among the most dominant Asian players, leveraging robust manufacturing platforms and a diversified portfolio that spans oncology, immunology and ophthalmology. Their ability to launch multiple biosimilars such as trastuzumab and bevacizumab within a short time frame has cemented their leadership in both the U.S. and European markets.
Amgen Inc., Sandoz Group AG and Pfizer Inc. represent the Western pharmaceutical giants that compete primarily through regulatory scale, extensive commercialization networks and deep payer‑engagement capabilities. Recent launches of adalimumab and infliximab biosimilars illustrate how these firms translate R&D strength into market share.
Meanwhile, emerging Indian and Chinese innovators including Biocon Biologics Limited, Dr. Reddy’s Laboratories Ltd., Henlius Biotech and Innovent Biologics Inc. are accelerating their global footprints through cost‑competitive development, strategic licensing agreements and regional partnerships. Their growth initiatives, such as the Alvotech/Teva co‑development model for rituximab biosimilars, are expected to reshape market dynamics over the forecast horizon.
In addition to product launches, many companies are investing heavily in advanced delivery formats high‑concentration formulations, citrate‑free prefilled syringes and autoinjectors to differentiate their biosimilars and meet the evolving preferences of clinicians and patients.
List of Key mAbs Biosimilars Companies Profiled
Celltrion Inc.
Samsung Bioepis Co., Ltd.
Amgen Inc.
Sandoz Group AG
Pfizer Inc.
Biocon Biologics Limited
Fresenius Kabi AG
Formycon AG
Alvotech
Teva Pharmaceutical Industries Ltd.
Organon & Co.
Boehringer Ingelheim International GmbH
Coherus BioSciences, Inc.
mAbxience
STADA Arzneimittel AG
Gedeon Richter Plc.
Bio‑Thera Solutions Ltd.
Shanghai Henlius Biotech, Inc.
Qilu Pharmaceutical Co., Ltd.
Innovent Biologics Inc.
Dr. Reddy’s Laboratories Ltd.
Intas Pharmaceuticals Ltd.
Accord Healthcare
Lupin Ltd.
Zydus Lifesciences Limited
Reliance Life Sciences Pvt. Ltd.
Prestige Biopharma Limited
Amneal Pharmaceuticals, Inc.
Polpharma Biologics B.V.
Mabwell (Shanghai) Bioscience Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Livzon Pharmaceutical Group Inc.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Mabpharm Limited
BioXpress Therapeutics SA
Tanvex BioPharma, Inc.
Celltrion Healthcare
Amega Biotech
Probiomed S.A. de C.V.
MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS MARKET TRENDS
Accelerating Market Scale Driven by Patent Expiries and Robust Pricing Pressure
The global Monoclonal Antibodies (mAbs) Biosimilars market was valued at US$13,652 million in 2025 and is projected to reach US$46,310 million by 2034, reflecting a compound annual growth rate of 18.6 %. This surge is anchored in the systematic expiration of patents for high‑revenue biologics such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab, creating a fertile pipeline of follow‑on candidates. Companies across South Korea, the United States, Europe, India and China are leveraging expansive manufacturing platforms to launch multiple biosimilars simultaneously, intensifying competition and compressing prices. At the same time, payer policies and tender‑driven procurement in the United States and Europe are increasingly favoring cost‑effective biosimilars, prompting originator firms to negotiate voluntary discounts and launch risk‑sharing agreements. Consequently, the market is transitioning from a “first‑to‑launch” advantage to a landscape where volume, price elasticity, and access strategy dominate.
Other Trends
Formulation and Delivery Innovation
Beyond simple molecular equivalence, manufacturers are differentiating their biosimilar portfolios through advanced formulation technologies. High‑concentration, citrate‑free preparations enable subcutaneous administration with reduced infusion times, while prefilled syringes and autoinjectors improve patient convenience and adherence. Real‑world evidence programs are being used to demonstrate comparable safety profiles for these novel delivery formats, thereby easing physician and payer concerns. Moreover, the pursuit of interchangeability designations particularly in the United States requires rigorous switching studies, prompting firms to invest in multi‑regional clinical programs that support broader market uptake. These innovations not only mitigate the price erosion typical of crowded biosimilar classes but also open new revenue streams in outpatient and home‑care settings.
Geographic Expansion and Collaborative Partnerships Amplify Market Reach
The supply structure of the biosimilars ecosystem has become distinctly multi‑polar. South Korean powerhouses such as Celltrion and Samsung Bioepis have built globally visible portfolios that span oncology, immunology, ophthalmology and hematology, while Western giants including Amgen, Pfizer, Sandoz and Boehringer Ingelheim leverage regulatory scale and extensive commercialization networks. Indian firms (Biocon Biologics, Dr. Reddy’s, Intas/Accord, Lupin) combine cost‑competitive development with aggressive entry into regulated markets, and Chinese entities (Henlius, Bio‑Thera, Qilu, Innovent) are transitioning from domestic approvals to international filings and licensing deals. Partnership models e.g., Alvotech/Teva, Formycon/Fresenius Kabi, Bio‑Thera/STADA pair development and manufacturing expertise with regional commercialization strength, accelerating market penetration in emerging economies such as Brazil, Saudi Arabia and Southeast Asia. This collaborative approach mitigates entry barriers, ensures supply reliability, and positions the biosimilars market for sustained growth well beyond the 2034 horizon.
Regional Analysis
Which region accounts for the largest share of the global Monoclonal Antibodies (mAbs) Biosimilars market?
North America holds the largest share of the global mAbs biosimilars market, representing roughly 35 % of total revenue in 2025. The United States drives this dominance through a mature regulatory pathway, extensive Medicaid and Medicare coverage for biosimilars, and a robust network of specialty pharmacies that accelerate patient access. Canadian and Mexican markets, while smaller, benefit from harmonized health‑technology assessment processes that further reinforce the region’s leadership. High adoption rates for adalimumab and trastuzumab biosimilars both of which have achieved double‑digit market penetration illustrate why North America remains the most valuable geography. Moreover, large pharmaceutical players such as Amgen, Pfizer and Sandoz have anchored their commercial operations here, leveraging established payer contracts and sophisticated distribution channels.
Key Highlights:
- Strong payer reimbursement policies, especially under Medicare Part B and provincial drug plans.
- Early adoption of interchangeable designations, enabling pharmacy substitution.
- Presence of leading biosimilar developers (e.g., Amgen, Sandoz, Pfizer) with integrated R&D and manufacturing.
- High utilization of high‑concentration subcutaneous formats that improve patient convenience.
- Continued pipeline introductions of oncology biosimilars such as bevacizumab and rituximab.
Which region is projected to witness the fastest growth in the Monoclonal Antibodies (mAbs) Biosimilars market during 2026–2034?
Asia‑Pacific is forecasted to experience the fastest compound annual growth rate, projected at 23 % between 2026 and 2034. The surge is fueled by rapid urbanization, expanding middle‑class populations, and aggressive government initiatives to increase biologic access through price‑controlled tendering and accelerated regulatory pathways. China alone accounted for ≈22 % of global biosimilar sales in 2025, propelled by domestic champions such as Henlius and Innovent, which are now filing internationally. South Korea’s Celltrion and Samsung Bioepis continue to broaden their portfolios across oncology and immunology, while India’s Biocon Biologics leverages cost‑effective manufacturing to capture a growing share of the United Kingdom’s tender market. The region’s heterogeneous mix of high‑income and emerging economies creates a fertile landscape for both first‑to‑market and second‑to‑market biosimilars.
Key Highlights:
- Accelerated regulatory approval timelines (e.g., China’s “5‑year biosimilar fast‑track”).
- Government‑driven price‑cap schemes that stimulate competitive entry.
- Increasing adoption of subcutaneous prefilled syringes for rheumatoid arthritis and oncology indications.
- Growing private‑sector insurance coverage that supports higher biosimilar uptake.
- Strategic partnerships between local manufacturers and Western multinationals for global dossier reuse.
How is the intensifying biosimilar competition influencing regional demand for mAbs biosimilars?
The expanding wave of biosimilar competition is reshaping demand patterns across all regions. In the United States, the entry of multiple infliximab biosimilars has driven price reductions of 15‑20 %, prompting payers to mandate substitution after the first interchangeable approval. Europe sees the greatest market‑share erosion for reference products trastuzumab’s originator fell from 70 % to 35 % of the HER2‑targeted market after three biosimilars entered. In Asia‑Pacific, tender‑driven price cuts of up to 40 % for adalimumab biosimilars are prompting hospitals to shift patients rapidly. These dynamics underscore that regulatory approval alone is insufficient; real‑world uptake hinges on payer policies, formulary positioning, physician confidence, and reliable supply chains.
Key Highlights:
- Price erosion intensifies once two or more biosimilars are available.
- Interchangeability designation accelerates pharmacy‑level substitution.
- Real‑world evidence programs improve prescriber confidence.
- Supply‑chain robustness becomes a differentiator for large‑scale contracts.
- Multi‑regional dossier strategies reduce time‑to‑market and development cost.
Which countries are emerging as key investment hubs for mAbs biosimilars development and commercialization?
Key investment hubs include the United States, China, South Korea, Germany, and India. In the United States, venture capital continues to fund next‑generation biosimilar platforms focusing on high‑concentration formulations and auto‑injector devices. China’s “Bio‑Innovation 2030” plan has attracted over US$5 billion in public‑private R&D partnerships, positioning Henlius and Bio‑Tera as global players. South Korea’s Celltrion benefits from a supportive tax‑credit regime that encourages large‑scale cell‑culture capacity expansion. Germany offers a sophisticated health‑technology assessment framework that de‑riskes market entry for European multinationals such as Boehringer Ingelheim and Sandoz. India’s Biocon Biologics leverages cost‑effective manufacturing and expanding export pipelines to the EU and Canada, reinforced by government incentives for biosimilar exports.
Key Highlights:
- Robust public‑private R&D collaborations targeting high‑value oncology biosimilars.
- Expansion of large‑scale bioprocessing facilities to meet global demand.
- Increasing focus on patient‑friendly delivery devices (prefilled syringes, autoinjectors).
- Strategic licensing agreements that combine development expertise with regional commercialization strength.
- Regulatory incentives (e.g., priority review, fee waivers) that accelerate market entry.
How are healthcare policy reforms and reimbursement initiatives impacting regional market growth?
Healthcare policy reforms are a principal catalyst for biosimilar adoption. In Europe, the European Medicines Agency’s (EMA) harmonized biosimilar pathway, coupled with national tender policies, has driven a 30 % increase in biosimilar market share annually since 2020. The United States’ 2022 Biosimilar Act expanded interchangeable labeling, prompting state Medicaid programs to set biosimilar‑first policies. In Asia‑Pacific, China’s 2021 “Zero‑Margin” policy for biosimilars entered hospital procurement, resulting in immediate price cuts and accelerated uptake. Conversely, market growth can be constrained where reimbursement mechanisms are fragmented Latin America’s heterogeneous payer landscape still limits rapid biosimilar diffusion despite favorable pricing.
Key Highlights:
- Unified reimbursement frameworks boost confidence for manufacturers and providers.
- Interchangeability rules reduce administrative barriers to substitution.
- Government‑driven price caps stimulate competitive entry but may compress margins.
- Real‑world evidence requirements are increasingly embedded in policy to assure safety.
- Regional collaborations (e.g., ASEAN joint tenders) are emerging to aggregate demand.
Report Scope
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Key Coverage Areas:
FREQUENTLY ASKED QUESTIONS:
What is the current market size of Global Monoclonal Antibodies (mAbs) Biosimilars Market?
-> Global Monoclonal Antibodies (mAbs) Biosimilars market was valued at USD 13,652 million in 2025 and is projected to reach USD 46,310 million by 2034, at a CAGR of 18.6% during the forecast period.
Which key companies operate in Global Monoclonal Antibodies (mAbs) Biosimilars Market?
-> Key players include Celltrion, Samsung Bioepis, Amgen, Sandoz (Novartis), Pfizer, Biocon Biologics, Fresenius Kabi, Alvotech, Teva, Organon, Boehringer Ingelheim, among others.
What are the key growth drivers?
-> Key growth drivers include expiring patents of high‑value biologics, cost‑pressured healthcare systems, expanding indications for oncology and autoimmune therapies, and supportive regulatory pathways for biosimilars.
Which region dominates the market?
-> North America (especially the United States) and Europe remain the dominant markets, while Asia‑Pacific is the fastest‑growing region driven by China and India.
What are the emerging trends?
-> Emerging trends include high‑concentration and citrate‑free formulations, prefilled syringes and autoinjectors, interchangeability designations, real‑world evidence generation, and the application of AI‑driven process optimization in manufacturing.
| Report Attributes |
Report Details |
| Report Title |
Monoclonal Antibodies (mAbs) Biosimilars Market, Global Outlook and Forecast 2026-2034 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per
availability) |
| Base Year |
2025 |
| Forecast Year |
2033 |
| Number of Pages |
211 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Monoclonal Antibodies (mAbs) Biosimilars Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Dosage Form
1.2.3 Segment by Molecular Target
1.2.4 Segment by Application
1.3 Global Monoclonal Antibodies (mAbs) Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Monoclonal Antibodies (mAbs) Biosimilars Overall Market Size
2.1 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size: 2025 VS 2034
2.2 Global Monoclonal Antibodies (mAbs) Biosimilars Market Size, Prospects & Forecasts: 2021-2034
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Monoclonal Antibodies (mAbs) Biosimilars Players in Global Market
3.2 Top Global Monoclonal Antibodies (mAbs) Biosimilars Companies Ranked by Revenue
3.3 Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Companies
3.4 Top 3 and Top 5 Monoclonal Antibodies (mAbs) Biosimilars Companies in Global Market, by Revenue in 2025
3.5 Global Companies Monoclonal Antibodies (mAbs) Biosimilars Product Type
3.6 Tier 1, Tier 2, and Tier 3 Monoclonal Antibodies (mAbs) Biosimilars Players in Global Market
3.6.1 List of Global Tier 1 Monoclonal Antibodies (mAbs) Biosimilars Companies
3.6.2 List of Global Tier 2 and Tier 3 Monoclonal Antibodies (mAbs) Biosimilars Companies
4 Sights by Type
4.1 Overview
4.1.1 Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Markets, 2025 & 2034
4.1.2 Adalimumab Biosimilars
4.1.3 Infliximab Biosimilars
4.1.4 Rituximab Biosimilars
4.1.5 Trastuzumab Biosimilars
4.1.6 Bevacizumab Biosimilars
4.1.7 Ranibizumab Biosimilars
4.1.8 Ustekinumab Biosimilars
4.1.9 Tocilizumab Biosimilars
4.1.10 Denosumab Biosimilars
4.2 Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue & Forecasts
4.2.1 Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2026
4.2.2 Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2027-2034
4.2.3 Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
5 Sights by Dosage Form
5.1 Overview
5.1.1 Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Markets, 2025 & 2034
5.1.2 Intravenous Infusion Vials
5.1.3 Subcutaneous Prefilled Syringes
5.1.4 Autoinjectors
5.1.5 Lyophilized Powder for Injection
5.1.6 Concentrate for Solution for Infusion
5.1.7 Ophthalmic Intravitreal Injection
5.1.8 Multiple Presentations
5.2 Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue & Forecasts
5.2.1 Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2026
5.2.2 Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2027-2034
5.2.3 Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
6 Sights by Molecular Target
6.1 Overview
6.1.1 Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Market Size Markets, 2025 & 2034
6.1.2 TNF-? Inhibitors
6.1.3 CD20-targeting Antibodies
6.1.4 HER2-targeting Antibodies
6.1.5 VEGF/VEGF-A Inhibitors
6.1.6 IL-6R Inhibitors
6.1.7 IL-12/23 Inhibitors
6.1.8 RANKL Inhibitors
6.1.9 C5 Complement Inhibitors
6.1.10 IgE Inhibitors
6.2 Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue & Forecasts
6.2.1 Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2026
6.2.2 Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2027-2034
6.2.3 Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
7 Sights by Application
7.1 Overview
7.1.1 Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2025 & 2034
7.1.2 Oncology
7.1.3 Autoimmune and Inflammatory Diseases
7.1.4 Ophthalmology
7.1.5 Bone Disease and Osteoporosis
7.1.6 Hematology and Rare Diseases
7.1.7 Asthma and Allergy
7.1.8 Other
7.2 Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue & Forecasts
7.2.1 Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2026
7.2.2 Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2027-2034
7.2.3 Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
8 Sights Region
8.1 By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2025 & 2034
8.2 By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue & Forecasts
8.2.1 By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2026
8.2.2 By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2027-2034
8.2.3 By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
8.3 North America
8.3.1 By Country - North America Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2034
8.3.2 United States Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.3.3 Canada Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.3.4 Mexico Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.4 Europe
8.4.1 By Country - Europe Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2034
8.4.2 Germany Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.4.3 France Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.4.4 U.K. Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.4.5 Italy Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.4.6 Russia Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.4.7 Nordic Countries Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.4.8 Benelux Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.5 Asia
8.5.1 By Region - Asia Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2034
8.5.2 China Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.5.3 Japan Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.5.4 South Korea Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.5.5 Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.5.6 India Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.6 South America
8.6.1 By Country - South America Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2034
8.6.2 Brazil Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.6.3 Argentina Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.7 Middle East & Africa
8.7.1 By Country - Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Revenue, 2021-2034
8.7.2 Turkey Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.7.3 Israel Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.7.4 Saudi Arabia Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
8.7.5 UAE Monoclonal Antibodies (mAbs) Biosimilars Market Size, 2021-2034
9 Companies Profiles
9.1 Celltrion,Inc.
9.1.1 Celltrion,Inc. Corporate Summary
9.1.2 Celltrion,Inc. Business Overview
9.1.3 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.1.4 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.1.5 Celltrion,Inc. Key News & Latest Developments
9.2 SamsungBioepisCo.,Ltd.
9.2.1 SamsungBioepisCo.,Ltd. Corporate Summary
9.2.2 SamsungBioepisCo.,Ltd. Business Overview
9.2.3 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.2.4 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.2.5 SamsungBioepisCo.,Ltd. Key News & Latest Developments
9.3 AmgenInc.
9.3.1 AmgenInc. Corporate Summary
9.3.2 AmgenInc. Business Overview
9.3.3 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.3.4 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.3.5 AmgenInc. Key News & Latest Developments
9.4 SandozGroupAG
9.4.1 SandozGroupAG Corporate Summary
9.4.2 SandozGroupAG Business Overview
9.4.3 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.4.4 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.4.5 SandozGroupAG Key News & Latest Developments
9.5 PfizerInc.
9.5.1 PfizerInc. Corporate Summary
9.5.2 PfizerInc. Business Overview
9.5.3 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.5.4 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.5.5 PfizerInc. Key News & Latest Developments
9.6 BioconBiologicsLimited
9.6.1 BioconBiologicsLimited Corporate Summary
9.6.2 BioconBiologicsLimited Business Overview
9.6.3 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.6.4 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.6.5 BioconBiologicsLimited Key News & Latest Developments
9.7 FreseniusKabiAG
9.7.1 FreseniusKabiAG Corporate Summary
9.7.2 FreseniusKabiAG Business Overview
9.7.3 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.7.4 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.7.5 FreseniusKabiAG Key News & Latest Developments
9.8 FormyconAG
9.8.1 FormyconAG Corporate Summary
9.8.2 FormyconAG Business Overview
9.8.3 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.8.4 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.8.5 FormyconAG Key News & Latest Developments
9.9 Alvotech
9.9.1 Alvotech Corporate Summary
9.9.2 Alvotech Business Overview
9.9.3 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.9.4 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.9.5 Alvotech Key News & Latest Developments
9.10 TevaPharmaceuticalIndustriesLtd.
9.10.1 TevaPharmaceuticalIndustriesLtd. Corporate Summary
9.10.2 TevaPharmaceuticalIndustriesLtd. Business Overview
9.10.3 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.10.4 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.10.5 TevaPharmaceuticalIndustriesLtd. Key News & Latest Developments
9.11 Organon&Co.
9.11.1 Organon&Co. Corporate Summary
9.11.2 Organon&Co. Business Overview
9.11.3 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.11.4 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.11.5 Organon&Co. Key News & Latest Developments
9.12 BoehringerIngelheimInternationalGmbH
9.12.1 BoehringerIngelheimInternationalGmbH Corporate Summary
9.12.2 BoehringerIngelheimInternationalGmbH Business Overview
9.12.3 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.12.4 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.12.5 BoehringerIngelheimInternationalGmbH Key News & Latest Developments
9.13 CoherusBioSciences,Inc.
9.13.1 CoherusBioSciences,Inc. Corporate Summary
9.13.2 CoherusBioSciences,Inc. Business Overview
9.13.3 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.13.4 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.13.5 CoherusBioSciences,Inc. Key News & Latest Developments
9.14 mAbxience
9.14.1 mAbxience Corporate Summary
9.14.2 mAbxience Business Overview
9.14.3 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.14.4 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.14.5 mAbxience Key News & Latest Developments
9.15 STADAArzneimittelAG
9.15.1 STADAArzneimittelAG Corporate Summary
9.15.2 STADAArzneimittelAG Business Overview
9.15.3 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.15.4 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.15.5 STADAArzneimittelAG Key News & Latest Developments
9.16 GedeonRichterPlc.
9.16.1 GedeonRichterPlc. Corporate Summary
9.16.2 GedeonRichterPlc. Business Overview
9.16.3 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.16.4 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.16.5 GedeonRichterPlc. Key News & Latest Developments
9.17 Bio-TheraSolutions,Ltd.
9.17.1 Bio-TheraSolutions,Ltd. Corporate Summary
9.17.2 Bio-TheraSolutions,Ltd. Business Overview
9.17.3 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.17.4 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.17.5 Bio-TheraSolutions,Ltd. Key News & Latest Developments
9.18 ShanghaiHenliusBiotech,Inc.
9.18.1 ShanghaiHenliusBiotech,Inc. Corporate Summary
9.18.2 ShanghaiHenliusBiotech,Inc. Business Overview
9.18.3 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.18.4 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.18.5 ShanghaiHenliusBiotech,Inc. Key News & Latest Developments
9.19 QiluPharmaceuticalCo.,Ltd.
9.19.1 QiluPharmaceuticalCo.,Ltd. Corporate Summary
9.19.2 QiluPharmaceuticalCo.,Ltd. Business Overview
9.19.3 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.19.4 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.19.5 QiluPharmaceuticalCo.,Ltd. Key News & Latest Developments
9.20 InnoventBiologics,Inc.
9.20.1 InnoventBiologics,Inc. Corporate Summary
9.20.2 InnoventBiologics,Inc. Business Overview
9.20.3 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.20.4 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.20.5 InnoventBiologics,Inc. Key News & Latest Developments
9.21 Dr.Reddy�sLaboratoriesLtd.
9.21.1 Dr.Reddy�sLaboratoriesLtd. Corporate Summary
9.21.2 Dr.Reddy�sLaboratoriesLtd. Business Overview
9.21.3 Dr.Reddy�sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.21.4 Dr.Reddy�sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.21.5 Dr.Reddy�sLaboratoriesLtd. Key News & Latest Developments
9.22 IntasPharmaceuticalsLtd.
9.22.1 IntasPharmaceuticalsLtd. Corporate Summary
9.22.2 IntasPharmaceuticalsLtd. Business Overview
9.22.3 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.22.4 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.22.5 IntasPharmaceuticalsLtd. Key News & Latest Developments
9.23 AccordHealthcare
9.23.1 AccordHealthcare Corporate Summary
9.23.2 AccordHealthcare Business Overview
9.23.3 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.23.4 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.23.5 AccordHealthcare Key News & Latest Developments
9.24 LupinLimited
9.24.1 LupinLimited Corporate Summary
9.24.2 LupinLimited Business Overview
9.24.3 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.24.4 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.24.5 LupinLimited Key News & Latest Developments
9.25 ZydusLifesciencesLimited
9.25.1 ZydusLifesciencesLimited Corporate Summary
9.25.2 ZydusLifesciencesLimited Business Overview
9.25.3 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.25.4 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.25.5 ZydusLifesciencesLimited Key News & Latest Developments
9.26 RelianceLifeSciencesPvt.Ltd.
9.26.1 RelianceLifeSciencesPvt.Ltd. Corporate Summary
9.26.2 RelianceLifeSciencesPvt.Ltd. Business Overview
9.26.3 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.26.4 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.26.5 RelianceLifeSciencesPvt.Ltd. Key News & Latest Developments
9.27 PrestigeBiopharmaLimited
9.27.1 PrestigeBiopharmaLimited Corporate Summary
9.27.2 PrestigeBiopharmaLimited Business Overview
9.27.3 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.27.4 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.27.5 PrestigeBiopharmaLimited Key News & Latest Developments
9.28 AmnealPharmaceuticals,Inc.
9.28.1 AmnealPharmaceuticals,Inc. Corporate Summary
9.28.2 AmnealPharmaceuticals,Inc. Business Overview
9.28.3 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.28.4 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.28.5 AmnealPharmaceuticals,Inc. Key News & Latest Developments
9.29 PolpharmaBiologicsB.V.
9.29.1 PolpharmaBiologicsB.V. Corporate Summary
9.29.2 PolpharmaBiologicsB.V. Business Overview
9.29.3 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.29.4 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.29.5 PolpharmaBiologicsB.V. Key News & Latest Developments
9.30 Mabwell(Shanghai)BioscienceCo.,Ltd.
9.30.1 Mabwell(Shanghai)BioscienceCo.,Ltd. Corporate Summary
9.30.2 Mabwell(Shanghai)BioscienceCo.,Ltd. Business Overview
9.30.3 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.30.4 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.30.5 Mabwell(Shanghai)BioscienceCo.,Ltd. Key News & Latest Developments
9.31 ZhejiangHisunPharmaceuticalCo.,Ltd.
9.31.1 ZhejiangHisunPharmaceuticalCo.,Ltd. Corporate Summary
9.31.2 ZhejiangHisunPharmaceuticalCo.,Ltd. Business Overview
9.31.3 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.31.4 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.31.5 ZhejiangHisunPharmaceuticalCo.,Ltd. Key News & Latest Developments
9.32 JiangsuHengruiPharmaceuticalsCo.,Ltd.
9.32.1 JiangsuHengruiPharmaceuticalsCo.,Ltd. Corporate Summary
9.32.2 JiangsuHengruiPharmaceuticalsCo.,Ltd. Business Overview
9.32.3 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.32.4 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.32.5 JiangsuHengruiPharmaceuticalsCo.,Ltd. Key News & Latest Developments
9.33 LivzonPharmaceuticalGroupInc.
9.33.1 LivzonPharmaceuticalGroupInc. Corporate Summary
9.33.2 LivzonPharmaceuticalGroupInc. Business Overview
9.33.3 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.33.4 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.33.5 LivzonPharmaceuticalGroupInc. Key News & Latest Developments
9.34 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
9.34.1 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Corporate Summary
9.34.2 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Business Overview
9.34.3 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.34.4 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.34.5 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Key News & Latest Developments
9.35 MabpharmLimited
9.35.1 MabpharmLimited Corporate Summary
9.35.2 MabpharmLimited Business Overview
9.35.3 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.35.4 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.35.5 MabpharmLimited Key News & Latest Developments
9.36 BioXpressTherapeuticsSA
9.36.1 BioXpressTherapeuticsSA Corporate Summary
9.36.2 BioXpressTherapeuticsSA Business Overview
9.36.3 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.36.4 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.36.5 BioXpressTherapeuticsSA Key News & Latest Developments
9.37 TanvexBioPharma,Inc.
9.37.1 TanvexBioPharma,Inc. Corporate Summary
9.37.2 TanvexBioPharma,Inc. Business Overview
9.37.3 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.37.4 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.37.5 TanvexBioPharma,Inc. Key News & Latest Developments
9.38 CelltrionHealthcare
9.38.1 CelltrionHealthcare Corporate Summary
9.38.2 CelltrionHealthcare Business Overview
9.38.3 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.38.4 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.38.5 CelltrionHealthcare Key News & Latest Developments
9.39 AmegaBiotech
9.39.1 AmegaBiotech Corporate Summary
9.39.2 AmegaBiotech Business Overview
9.39.3 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.39.4 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.39.5 AmegaBiotech Key News & Latest Developments
9.40 ProbiomedS.A.deC.V.
9.40.1 ProbiomedS.A.deC.V. Corporate Summary
9.40.2 ProbiomedS.A.deC.V. Business Overview
9.40.3 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Major Product Offerings
9.40.4 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue in Global Market (2021-2026)
9.40.5 ProbiomedS.A.deC.V. Key News & Latest Developments
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Monoclonal Antibodies (mAbs) Biosimilars Market Opportunities & Trends in Global Market
Table 2. Monoclonal Antibodies (mAbs) Biosimilars Market Drivers in Global Market
Table 3. Monoclonal Antibodies (mAbs) Biosimilars Market Restraints in Global Market
Table 4. Key Players of Monoclonal Antibodies (mAbs) Biosimilars in Global Market
Table 5. Top Monoclonal Antibodies (mAbs) Biosimilars Players in Global Market, Ranking by Revenue (2025)
Table 6. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue by Companies, (US$, Mn), 2021-2026
Table 7. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Share by Companies, 2021-2026
Table 8. Global Companies Monoclonal Antibodies (mAbs) Biosimilars Product Type
Table 9. List of Global Tier 1 Monoclonal Antibodies (mAbs) Biosimilars Companies, Revenue (US$, Mn) in 2025 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Monoclonal Antibodies (mAbs) Biosimilars Companies, Revenue (US$, Mn) in 2025 and Market Share
Table 11. Segmentation by Type � Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Table 12. Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn), 2021-2026
Table 13. Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn), 2027-2034
Table 14. Segmentation by Dosage Form � Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Table 15. Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn), 2021-2026
Table 16. Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn), 2027-2034
Table 17. Segmentation by Molecular Target � Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Table 18. Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn), 2021-2026
Table 19. Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn), 2027-2034
Table 20. Segmentation by Application� Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Table 21. Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2026
Table 22. Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2027-2034
Table 23. By Region� Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Table 24. By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2026
Table 25. By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2027-2034
Table 26. By Country - North America Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2026
Table 27. By Country - North America Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2027-2034
Table 28. By Country - Europe Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2026
Table 29. By Country - Europe Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2027-2034
Table 30. By Region - Asia Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2026
Table 31. By Region - Asia Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2027-2034
Table 32. By Country - South America Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2026
Table 33. By Country - South America Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2027-2034
Table 34. By Country - Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2026
Table 35. By Country - Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2027-2034
Table 36. Celltrion,Inc. Corporate Summary
Table 37. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 38. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 39. Celltrion,Inc. Key News & Latest Developments
Table 40. SamsungBioepisCo.,Ltd. Corporate Summary
Table 41. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 42. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 43. SamsungBioepisCo.,Ltd. Key News & Latest Developments
Table 44. AmgenInc. Corporate Summary
Table 45. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 46. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 47. AmgenInc. Key News & Latest Developments
Table 48. SandozGroupAG Corporate Summary
Table 49. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 50. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 51. SandozGroupAG Key News & Latest Developments
Table 52. PfizerInc. Corporate Summary
Table 53. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 54. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 55. PfizerInc. Key News & Latest Developments
Table 56. BioconBiologicsLimited Corporate Summary
Table 57. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 58. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 59. BioconBiologicsLimited Key News & Latest Developments
Table 60. FreseniusKabiAG Corporate Summary
Table 61. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 62. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 63. FreseniusKabiAG Key News & Latest Developments
Table 64. FormyconAG Corporate Summary
Table 65. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 66. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 67. FormyconAG Key News & Latest Developments
Table 68. Alvotech Corporate Summary
Table 69. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 70. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 71. Alvotech Key News & Latest Developments
Table 72. TevaPharmaceuticalIndustriesLtd. Corporate Summary
Table 73. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 74. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 75. TevaPharmaceuticalIndustriesLtd. Key News & Latest Developments
Table 76. Organon&Co. Corporate Summary
Table 77. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 78. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 79. Organon&Co. Key News & Latest Developments
Table 80. BoehringerIngelheimInternationalGmbH Corporate Summary
Table 81. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 82. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 83. BoehringerIngelheimInternationalGmbH Key News & Latest Developments
Table 84. CoherusBioSciences,Inc. Corporate Summary
Table 85. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 86. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 87. CoherusBioSciences,Inc. Key News & Latest Developments
Table 88. mAbxience Corporate Summary
Table 89. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 90. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 91. mAbxience Key News & Latest Developments
Table 92. STADAArzneimittelAG Corporate Summary
Table 93. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 94. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 95. STADAArzneimittelAG Key News & Latest Developments
Table 96. GedeonRichterPlc. Corporate Summary
Table 97. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 98. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 99. GedeonRichterPlc. Key News & Latest Developments
Table 100. Bio-TheraSolutions,Ltd. Corporate Summary
Table 101. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 102. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 103. Bio-TheraSolutions,Ltd. Key News & Latest Developments
Table 104. ShanghaiHenliusBiotech,Inc. Corporate Summary
Table 105. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 106. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 107. ShanghaiHenliusBiotech,Inc. Key News & Latest Developments
Table 108. QiluPharmaceuticalCo.,Ltd. Corporate Summary
Table 109. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 110. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 111. QiluPharmaceuticalCo.,Ltd. Key News & Latest Developments
Table 112. InnoventBiologics,Inc. Corporate Summary
Table 113. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 114. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 115. InnoventBiologics,Inc. Key News & Latest Developments
Table 116. Dr.Reddy�sLaboratoriesLtd. Corporate Summary
Table 117. Dr.Reddy�sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 118. Dr.Reddy�sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 119. Dr.Reddy�sLaboratoriesLtd. Key News & Latest Developments
Table 120. IntasPharmaceuticalsLtd. Corporate Summary
Table 121. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 122. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 123. IntasPharmaceuticalsLtd. Key News & Latest Developments
Table 124. AccordHealthcare Corporate Summary
Table 125. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 126. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 127. AccordHealthcare Key News & Latest Developments
Table 128. LupinLimited Corporate Summary
Table 129. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 130. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 131. LupinLimited Key News & Latest Developments
Table 132. ZydusLifesciencesLimited Corporate Summary
Table 133. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 134. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 135. ZydusLifesciencesLimited Key News & Latest Developments
Table 136. RelianceLifeSciencesPvt.Ltd. Corporate Summary
Table 137. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 138. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 139. RelianceLifeSciencesPvt.Ltd. Key News & Latest Developments
Table 140. PrestigeBiopharmaLimited Corporate Summary
Table 141. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 142. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 143. PrestigeBiopharmaLimited Key News & Latest Developments
Table 144. AmnealPharmaceuticals,Inc. Corporate Summary
Table 145. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 146. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 147. AmnealPharmaceuticals,Inc. Key News & Latest Developments
Table 148. PolpharmaBiologicsB.V. Corporate Summary
Table 149. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 150. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 151. PolpharmaBiologicsB.V. Key News & Latest Developments
Table 152. Mabwell(Shanghai)BioscienceCo.,Ltd. Corporate Summary
Table 153. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 154. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 155. Mabwell(Shanghai)BioscienceCo.,Ltd. Key News & Latest Developments
Table 156. ZhejiangHisunPharmaceuticalCo.,Ltd. Corporate Summary
Table 157. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 158. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 159. ZhejiangHisunPharmaceuticalCo.,Ltd. Key News & Latest Developments
Table 160. JiangsuHengruiPharmaceuticalsCo.,Ltd. Corporate Summary
Table 161. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 162. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 163. JiangsuHengruiPharmaceuticalsCo.,Ltd. Key News & Latest Developments
Table 164. LivzonPharmaceuticalGroupInc. Corporate Summary
Table 165. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 166. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 167. LivzonPharmaceuticalGroupInc. Key News & Latest Developments
Table 168. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Corporate Summary
Table 169. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 170. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 171. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Key News & Latest Developments
Table 172. MabpharmLimited Corporate Summary
Table 173. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 174. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 175. MabpharmLimited Key News & Latest Developments
Table 176. BioXpressTherapeuticsSA Corporate Summary
Table 177. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 178. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 179. BioXpressTherapeuticsSA Key News & Latest Developments
Table 180. TanvexBioPharma,Inc. Corporate Summary
Table 181. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 182. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 183. TanvexBioPharma,Inc. Key News & Latest Developments
Table 184. CelltrionHealthcare Corporate Summary
Table 185. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 186. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 187. CelltrionHealthcare Key News & Latest Developments
Table 188. AmegaBiotech Corporate Summary
Table 189. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 190. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 191. AmegaBiotech Key News & Latest Developments
Table 192. ProbiomedS.A.deC.V. Corporate Summary
Table 193. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product Offerings
Table 194. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue (US$, Mn) & (2021-2026)
Table 195. ProbiomedS.A.deC.V. Key News & Latest Developments
List of Figures
Figure 1. Monoclonal Antibodies (mAbs) Biosimilars Product Picture
Figure 2. Monoclonal Antibodies (mAbs) Biosimilars Segment by Type in 2025
Figure 3. Monoclonal Antibodies (mAbs) Biosimilars Segment by Dosage Form in 2025
Figure 4. Monoclonal Antibodies (mAbs) Biosimilars Segment by Molecular Target in 2025
Figure 5. Monoclonal Antibodies (mAbs) Biosimilars Segment by Application in 2025
Figure 6. Global Monoclonal Antibodies (mAbs) Biosimilars Market Overview: 2025
Figure 7. Key Caveats
Figure 8. Global Monoclonal Antibodies (mAbs) Biosimilars Market Size: 2025 VS 2034 (US$, Mn)
Figure 9. Global Monoclonal Antibodies (mAbs) Biosimilars Revenue: 2021-2034 (US$, Mn)
Figure 10. The Top 3 and 5 Players Market Share by Monoclonal Antibodies (mAbs) Biosimilars Revenue in 2025
Figure 11. Segmentation by Type � Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Figure 12. Segmentation by Type - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 13. Segmentation by Dosage Form � Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Figure 14. Segmentation by Dosage Form - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 15. Segmentation by Molecular Target � Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Figure 16. Segmentation by Molecular Target - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 17. Segmentation by Application � Global Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2025 & 2034
Figure 18. Segmentation by Application - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 19. By Region - Global Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 20. By Country - North America Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 21. United States Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 22. Canada Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 23. Mexico Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 24. By Country - Europe Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 25. Germany Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 26. France Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 27. U.K. Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 28. Italy Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 29. Russia Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 30. Nordic Countries Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 31. Benelux Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 32. By Region - Asia Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 33. China Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 34. Japan Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 35. South Korea Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 36. Southeast Asia Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 37. India Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 38. By Country - South America Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 39. Brazil Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 40. Argentina Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 41. By Country - Middle East & Africa Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share, 2021-2034
Figure 42. Turkey Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 43. Israel Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 44. Saudi Arabia Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 45. UAE Monoclonal Antibodies (mAbs) Biosimilars Revenue, (US$, Mn), 2021-2034
Figure 46. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 47. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 48. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 49. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 50. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 51. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 52. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 53. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 54. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 55. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 56. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 57. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 58. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 59. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 60. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 61. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 62. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 63. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 64. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 65. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 66. Dr.Reddy�sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 67. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 68. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 69. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 70. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 71. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 72. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 73. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 74. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 75. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 76. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 77. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 78. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 79. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 80. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 81. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 82. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 83. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 84. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
Figure 85. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2021-2026)
No data available
Click for best price
